Cambrian Biopharma isn't a research company in the way Altos Labs or Unity Biotechnology are, it's a holding company that identifies promising aging-related drug assets, often licensed from academic labs, and spins each one out into its own dedicated subsidiary with its own leadership and funding. The parent company's role is capital allocation and portfolio construction across a set of independent bets rather than a single therapeutic thesis of its own.
This model has a straightforward logic: individual longevity drug candidates fail often, for the same reasons drugs fail in any therapeutic area, but a portfolio spread across many distinct mechanisms and disease targets is less exposed to any single failure than a company built around one approach. It's the closest thing in this directory to a venture-portfolio model applied directly to biotech asset creation rather than just biotech investing.
Life Biosciences uses a related subsidiary structure, but ties its subsidiaries more closely to a shared aging-biology thesis; Cambrian's subsidiaries can pursue a wider range of unrelated disease targets as long as each has a credible aging-adjacent scientific rationale.